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Abstract 
Introduction The molecular and pharmacological complexity of biologics modifying-
antirheumatic drugs used for the management of rheumatoid arthritis (RA) favors the 
occurrence of adverse drug reactions (ADRs), which should be constantly monitored in post-
marketing safety studies.  
Objective The aim of this study was to identify signals of disproportionate reporting (SDR) of 
clinical relevance related to the use of biologic drugs approved for RA and other autoimmune 
diseases.  
Methods All suspected ADRs registered in the FDA Adverse Event Reporting System (FAERS) 
between January 2003 and June 2016 were collected. The reporting odds ratio (ROR) was used 
as a measure of disproportionality to identify possible SDRs related to biologics. Those 
involving Important Medical Events (IME) and Designated Medical Events (DME) were 
prioritized.  
Results In total, 2,602 SDRs were prioritized. The most commonly reported were 'Infections 
and infestations' (32.2%) and 'Neoplasms benign, malignant, and unspecified' (20.4%), and 
were mainly related to use of infliximab (25.3%, p < 0.001, and 28.8%, p = 0.002, respectively). 
Sixty-three signals involving DMEs were identified, most of which were related to rituximab 
(n = 27), and were mainly due to ‘blood disorders’. Amongst the DMEs detected for more than 
one biologic, 'intestinal perforation' and 'pulmonary fibrosis' were related to most of them.   
Conclusions The results of this study highlight possible safety issues associated with biologics, 
whose relationship should be more thoroughly investigated. Our results contribute to future 
research on the identification of clinically relevant risks associated with these drugs, and may 
help contribute to their rational and safe use. 
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Key Points 
This study identified 2,602 Important Medical Events (IME) of clinical relevance related to the 
use of biologics for RA in the analysis of the database FAERS.  
We highlighted a high frequency of signals of disproportionate reporting (SDR) involving 
adverse events, such as infections and neoplasms, mainly related to the use infliximab. 
The results of our study indicated possible safety issues that need to be further investigated for 
identification of clinically relevant risks amongst these biologic drugs. 
 
1. Introduction 
The development of biologic disease-modifying antirheumatic drugs in the last two decades 
was considered a revolution in the treatment of rheumatologic/autoimmune diseases. These 
drugs have enabled better control of disease progression in rheumatoid arthritis (RA) [1, 2], 
ulcerative colitis, Chron’s disease [3], psoriasis [4], psoriatic arthritis, and ankylosing 
spondylitis [5]. However, they are associated with serious, rare, and unpredictable adverse 
events, such as risk of serious infections [6, 7], what makes it difficult to detect and evaluate 
their safety only by pre-marketing trials [8]. 
  Therefore, post-marketing data are crucial to elucidate the true safety profile of these 
therapies in patients [9]. In this context, spontaneous reports of adverse events organized within 
databases represent a valuable source of information for post-marketing surveillance [10] as 
they allow early identification of possible safety signals. These signals are defined as suspected 
adverse drug reactions (ADRs) as the relationship between these reactions and the drugs are 
still not well established and require further analysis [11, 12]. For the detection of an unknown 
adverse reaction, the signal of disproportionate reporting (SDR) is firstly observed. Then the 
accumulation of data strengthens its signal, which is thus validated in order to establish the 
causality between the ADR and the specific therapy. Having this information makes it possible 
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to confirm, quantify and explain this interaction. This process can be slow and long, and may 
last for years. 
 In order to evaluate SDRs of biologics used in rheumatologic/autoimmune diseases, 
we carried out a descriptive study of spontaneous reports of adverse events from the Food and 
Drug Administration (FDA) Adverse Event Reporting System (FAERS) database. 
 
2 Methods 
2.1 Data Source 
 Data were obtained from the FAERS, which records all reports of suspected ADRs 
occurring in the United States of America, as well as serious ADRs reported by other countries.  
 The data from these reports are divided in seven groups: patient demographic and 
administrative information (DEMO); drug/biologic information (DRUG); preferred terms 
(PTs) of the Medical Dictionary for Regulatory Activities (MedDRA) for the events (REAC); 
patient outcomes for the event (OUTC); indications of use (diagnosis) for the reported drugs 
(INDI); therapy start dates and end dates (THER); and report sources for the event (RPSR). The 
records comply with the International Conference on Harmonization of Technical 
Requirements for Registration of Pharmaceutical Products for Human Use (ICH) E2B [13] and 
are available for public access in quarterly archives on the FDA website [14]. 
 
2.2 Data preparation 
 The drugs included in this study were abatacept, adalimumab, anakinra, certolizumab 
pegol, etanercept, golimumab, infliximab, rituximab and tocilizumab [Electronic 
Supplementary Material Online Table S1]. Generic and brand names of all the approved 
biologics for RA, as well as their acronyms, were used in this study. They were identified 
through searches on specialized websites, regulatory agencies (FDA and European Medicines 
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Agency - EMA), and clinical guidelines for treatment of RA (last updated in June 2016) [15-
22]. These names were used as keywords to identify notifications related to these biologics. All 
notifications recorded between January/2003 and June/2016 in which specific biologics were 
considered the primary or secondary suspect (PS or SS, respectively) cause of ADR were 
collected.  
 The files from January/2003 to September/2012 were made available by Wong et al., 
who standardized the names of the drugs reported within this period [23]. The files from 
October/2012 to June/2016 were in turn directly downloaded from the FDA website. Data were 
managed using Microsoft Access® version 15.0.  
 Patients’ ages were standardized in years. The notifying countries were identified by 
codes according to International Organization for Standardization (ISO) 3166 [24]. Adverse 
events and indications of use were classified by preferred terms in the MedDRA® version 19.1 
dictionary from the ICH [25]. Outcomes were classified according to seriousness in: death, life-
threatening, hospitalization (initial or prolonged), disability, congenital anomaly, requiring 
intervention to prevent, permanent impairment or damage, or other Important Medical Events 
(IMEs). 
 Records without the notification or case number, and without the name of the 
suspected drug or the adverse reaction, were excluded. Reports that did not include the patient's 
age, or referred to patients younger than 18 years or older than 74 years, were excluded to 
minimize bias due to important physiological changes due to age and susceptibility to ADRs 
[26, 27]. Duplicate reports were deleted prior data analysis [9]. All reports with the same case 
number and suspect drug were identified and only the most recent version was documented 
[28]. Cases with the same date of the event, age and gender of the patient, notifying country, 
drug name, and suspected adverse event, were identified and documented as a single record 
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[29]. In the final table, only one record was maintained for each drug-adverse reaction 
combination reported, corresponding to the number of ADRs analyzed.  
 
2.3 Data analysis 
 Data were analyzed considering the main recommendations described in Good Signal 
Detection Practices [30]. The reports were separated into three groups according to age (18-35, 
36-64, and 65-74 years), which were divided further according to the patient’s gender (female, 
male, and uninformed), resulting in nine subgroups [31]. In each subgroup, the reporting odds 
ratio (ROR) was used as a measure of disproportionality between the notifications for each 
biologic versus the notifications for all other drugs registered in FAERS.  
 A two-by-two contingency table was composed for each adverse event comparing: (a) 
notifications of the biologic drug with the evaluated ADR; (b) notifications of the biologic drug 
with other ADRs; (c) notifications of other drugs with the evaluated ADR; and (d) notifications 
of other drugs with other ADRs.  A 95% confidence interval (95% CI) was considered. An 
adverse event was associated with one of the biologics SDR when the lower ROR confidence 
interval was greater than 1, and the number of notifications for this combination was greater 
than 2 [32]. These signals are defined as suspected ADRs in which the relationship between 
these reactions and the drugs are still not well established and require further analysis [11, 12]. 
Safety-relevant clinical signals were prioritized. IMEs and Designated Medical Events (DMEs) 
were selected according to the lists developed and updated by the EMA [33, 34]. All statistical 
analyses were performed using Microsoft Excel®, and a p-value < 0.05 was defined as the 
threshold for statistical significance. 
 ADRs were grouped by System Organ Classes (SOC) according to the MedDRA® 
dictionary. The frequency of signs in the most common SOCs were analyzed through the 
binomial proportion test, using the software Action® and Microsoft Excel®. The analyses were 
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conducted considering the drug that presented the highest frequency compared to the other 
drugs. 
 
3 Results 
Within the adopted time range, 8,464,871 spontaneous reports were identified in the FAERS in 
which the drug was considered as primary or secondary suspect cause of ADR.  1,326,337 
(16.1%) reports were excluded in the process of standardization and removal of duplicates. Also 
excluded were 2,849,75 (33.7%) reports that did not describe the patient’s age , 249,992 (3.0%) 
reports  referring to patients aged under 18 years, and 676,839 (8.0%) reports related to patients 
aged over 74 years. 
In total, 3,326,628 reports (17,075,380 ADRs) were included in this study, of which 
411,063 (1,339,374 ADRs) referred to biologics approved for the treatment of rheumatoid 
arthritis and other autoimmune diseases, and 2,915,565 reports (15,736,006 ADRs) notified for 
other medications. Biologics represented 12.4% of the reports analyzed, involving 10,103 
different types of adverse events (amongst the 1,339,374 ADRs). 
 
3.1 General characteristics of spontaneous reports for biologics 
 Considering  the 411,063 spontaneous reports identified for biologics for RA and 
other autoimmune diseases (Table 1), the mean age of affected patients was 51.1 years (standard 
deviation, SD=14.2 years), with most patients aged between 36-64 years in 259,215 (63.1%) of 
the reports . Of the total number of reports, 268,360 (65.3%) were in females.  
 The consumers were the main contributors in the reporting process, registering 
188,963 (46.0%) of the reports, followed by physicians, 141,386 (34.4%) reports. Other health 
professionals notified 61,601 (15.0%) reports and pharmacists 7,285 (1.8%). 
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 Most reports came from North America, 235,230 (57.2%), with the United States 
predominating as the most common notifying country, 215,331(52.4%). Europe was 
responsible for 44,823 (10.9%) of the reports, whilst 22,972 (5.6%) were registered by other 
continents. More than one quarter, 108,038 (26.3%) reports, did not state the notifying country.  
By the analysis of the distribution of spontaneous reports for each biologic, tumor 
necrosis factor inhibitor (TNFi) drugs were the suspected cause in 380,900 (92.7%) of them. 
Etanercept was the most frequently mentioned, and was a suspected drug in 172,225 (41.9%) 
reports, followed by adalimumab 148,586 (36.1%), and infliximab 41,920 (10.2 %). 
Certolizumab pegol was notified in 11,419 (2.8%) reports and golimumab in 6,750 (1.6%). 
Amongst the non-TNFi drugs, rituximab was a suspected drug in 19,788 (4.8%), followed by 
abatacept in 9,200 (2.2%), tocilizumab in 6,719(1.6%) and anakinra in 655 (0.2%) (Table 1). 
See [Electronic Supplementary Material Online - Table S2] for more details. 
Serious outcomes were found in 177,031 (43.1%) of the reports. The most frequent 
serious outcomes within these cases were IMEs and hospitalization or prolongation (108,982 
(26.5%) and 83,093 (20.2%), respectively). Risk to life was notified in 7,428 (1.8%) of the 
reports, death in 13,192 (3.2%), disability in 4,208 (1.0%), and need for intervention to prevent 
permanent damage in 1,560 (0.4%). There were 75 reports of congenital anomalies for the 
biologics analyzed. 
Of the reports, 53,027 (30.0%) were related to etanercept, whilst 45,284 (25.6%) were 
related to adalimumab, 39,832 (22.5%) to infliximab, 7,374 (4.2%) to certolizumab pegol, and 
5,193 (2.9%) to golimumab. Amongst the non-TNFi, rituximab was notified in 19,425 (11.0%) 
of the serious reports, tocilizumab in 6,466 (3.7%), abatacept in 5,016 (2.8%), and anakinra in 
547 (0.3%) (Table 1). 
Analyzing the number of reports by indication of use for each biologic, RA 
predominated in the reports by tocilizumab (84.6%), abatacept (68.0%), anakinra (59.4%) 
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etanercept (54.6%), and golimumab (45.5%). A similar frequency of indication of use was 
reported for both RA and Crohn's disease for infliximab (25.2% and 29.2%, respectively), and 
certolizumab pegol (35.8% and 43.9%, respectively). For adalimumab, in 31.8% of the reports 
the indication of use was RA, in 27.6% it was Crohn's disease, and in 22.9% Psoriatic disease.  
The indications for rituximab were very different from the other biologics, with 19.0% of 
reports designing for use in RA and 68.9% for other conditions with low frequency, of which 
12.4% were non-Hodgkin's lymphoma and 10.1% chronic lymphocytic leukemia [Electronic 
Supplementary Material Online – Table S2]. More details about DME associated with 
Rituximab by calculated ROR are described in Electronic Supplementary Material Online – 
Table S3. 
 
3.2 Disproportionality analysis for biologics 
 Of the 10,103 different adverse events reported for the biologics, 3,103 were 
statistically related to these drugs after calculation of the ROR. Of these, 1,223 were on the IME 
list, corresponding to 2,602 SDRs considered of clinical relevance.  
 Disproportionality analysis was performed on subgroups of age and sex amongst the 
2,602 SDRs. 1,139 (43.8%) were detected in more than one subgroup analyzed, and 1,463 
(56.2%) were detected in only one of these subgroups. The majority of the SDRs related to only 
one of the subgroups were for female and male patients aged 18-35 years, comprising 496 
(33.9%) and 38pml1 (26.0%), respectively.  The subgroup aged 65-74 years were responsible 
for 239 (16.3%) and 172 (11,8%) of the SDRs for women and men, respectively. The analysis 
of subgroups of patients aged 18-35 also contributed to identify 107 (7.3%) SDRs among 
women and 61 (4.2%) among men. In the subgroups for which the sex was not informed, it was 
possible to detect 5 SDRs for patients aged 36-64 years and 2 SDRs for patients aged 18-35 
years.  Infliximab and rituximab were the most frequent drugs, related to 646 (24.8%) and 
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529 (20.3%) of the detected SDRs, respectively. Amongst the other TNFi, 421 (16.2%) signals 
were detected for adalimumab, 329 (12.6%) for etanercept, 172 (6.6%) for certolizumab pegol, 
and 119 (4.6%) for golimumab. Amongst the other non-TNFi, 199 (7.6%) SDRs referred to 
tocilizumab, 136 (5.2%) to abatacept, and 51 (2.0%) to anakinra.  
Figure 1 presents a comparison of the total number of reports and reports involving 
serious ADR notified (Table 1), in addition to the number of SDRs for biological TNFi and 
non-TNFi (Table 2). More than 75% of the reports were related to etanercept and adalimumab, 
although these two drugs were associated with a lower proportion of serious reports when 
compared with other biologics. Infliximab and rituximab showed a higher proportion of serious 
reports, and comprised together for almost half of the safety problems detected (24.8% and 
20.3%, respectively). For the other biologics, a greater proportion of serious events were also 
observed; however, the low relative frequency of events compared to the total ADRs hampered 
a deeper comparative analysis amongst these other drugs. 
When grouped by SOC (Table 2), most of the SDRs belonged to the SOCs 'infections 
and infestations' (32.2%) and ´malignant and unspecified benign neoplasms' (20.4%). 
'Gastrointestinal disorders' and 'surgical and medical procedures' accounted for 8.2%, nervous 
system disorders for 4.5%, respiratory, thoracic and mediastinal disorders for 3.2%, and 
musculoskeletal and connective tissue disorders for 3.2%, whilst the other SOCs had a 
frequency less than 3% in the total SDRs detected.  
 Statistically significant differences between infliximab and other biologics were 
observed for the SOCs 'infections and infestations' and 'neoplasms benign, malignant, and 
unspecified'. These SOCs were more frequent within the signals for infliximab in comparison 
to other biologics (25.3%; p < 0.001 and 28.8%; p = 0.002, respectively). An association 
between infliximab and progressive multifocal leukoencephalopathy (PML)  was also detected 
in male patients aged 65-74 years (data not shown). 
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In the SOC 'blood and lymphatic system disorders’, rituximab stood out in comparison 
to the other drugs. It was described in 29 out of the 51 detected signals (p < 0.001), despite the 
low overall frequency of this SOC (2.0%). 
Thirty-five DMEs were reported, of which 13 were associated with TNFi (Table 3) and 
32 with non- TNFi (Table 4), which represents 63 detected SDRs (for complete table with ROR 
values by subgroups see Electronic Supplementary Material Online – Tables S4 and S5). 
Rituximab was associated with 27 signals. Fifteen out of the 20 DMEs associated with only one 
biologic referred to rituximab; 10 of which belonged to the SOC 'blood and lymphatic system 
disorders'. Acute pancreatitis and drug-induced liver injury were only associated with 
tocilizumab, whilst autoimmune hepatitis and angioedema were associated with infliximab, and 
hepatic necrosis with anakinra. Amongst the 14 DMEs described for more than one drug, most 
were associated with intestinal perforation (infliximab, adalimumab, certolizumab pegol, 
golimumab, rituximab, abatacept, and tocilizumab) and pulmonary fibrosis (infliximab, 
etanercept, adalimumab, certolizumab pegol, rituximab, abatacept, and tocilizumab). Overall, 
the frequency of DMEs related to these biologic drugs was low, being that the association 
between rituximab and progressive multifocal leukoencephalopathy was the most reported, 
representing 10.7% of the total reports obtained on the FAERS. 
 
4 Discussion 
 Our study has provided an overview of the possible safety concerns associated with 
biologics approved for the treatment of RA. Our findings are based on the reporting of ADRs 
of major clinical relevance. 
The main divergence between our results and previous studies was the low frequency 
of SOCs related to 'general disorders and administration site conditions', probably due to the 
prioritization of the detection of serious adverse events. Several studies have highlighted this 
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SOC as an important group of ADRs associated with the use of biologics, mainly due to the 
high occurrence of administration site reactions [9, 28, 35, 36]. However, these ADRs usually 
do not result in serious outcomes or treatment discontinuation [29]. Moreover, in most studies, 
the detection of SDRs was performed by classifying suspected ADRs by their SOC term, which 
is a broader concept of adverse reaction, and covers both serious and non-serious ADRs. On 
the other hand, in our study, we detected signals using the PT, a more specific concept used to 
define an ADR [37]. Hence, we were able to provide a better evidence regarding prioritization 
for adverse events management to guide clinicians, regulators, and industry to focus on the 
most relevant signals. 
Our focus on the occurrence of serious events may also explain why infliximab and 
rituximab were associated with higher frequencies of safety problems, despite the similar 
commercialization times between these and other drugs, especially etanercept. Although 
etanercept had the highest percentage of ADRs reported, which may be due to increased use of 
this drug in recent years, this medication presented low proportion of serious events and SDRs, 
which may indicate a lower occurrence of serious events associated with its use. Registry 
studies have also shown a lower rate of discontinuation due to adverse events for etanercept in 
comparison to infliximab and adalimumab [38]. 
Our study also highlighted a large frequency of infections and neoplasms. Other studies 
have also reported these ADRs as major safety concerns associated with the use of biologic 
drugs [9, 28, 35, 36, 39-41]; however, there is still no consensus on the actual risk and the role 
of individual differences regarding these drugs, which suggests that these safety issues are still 
not well established and require further investigation [8, 42]. 
Despite belonging to the same class of drugs, TNFi agents present some particularities 
in their composition and mechanisms of action. Adalimumab, golimumab and infliximab are 
monoclonal anti-TNF antibodies (the first two are totally humanized and the last one is human–
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murine), whilst etanercept consists in a soluble TNF receptor protein with an Fc fragment, and 
certolizumab pegol is a Fab’ fragment of TNF alpha, with no Fc fraction. These characteristics 
provide to TNFi agents different specificity, affinity and avidity for TNF-alpha, which may 
explain the reason for the occurrence of some specific adverse events. For instance, studies have 
shown that infliximab promotes granulomatous infections more often when compared to other 
TNFi [43-45]. In our study, the statistically significant association between infliximab use and 
infections and neoplasms may reflect an increased risk of specific adverse events for this drug. 
Nevertheless, it is still not established whether these differences are related to the drug’s 
mechanism of action (monoclonal antibody versus receptor) or to the pharmacokinetics 
(intravenous versus subcutaneous use) [8, 46]. Regarding neoplasms, some studies have 
identified a higher frequency of TNFi-related skin cancer [47], and also found a greater risk 
associated with infliximab compared to etanercept [48]. However, it is difficult to determine 
causality of neoplasms as they can occur naturally in the population and are usually developed 
after the exposure but without clear temporal relationship between the development of the 
neoplasm and the use of the drugs. Moreover, in these cases, the study of spontaneous 
notifications is not considered the most appropriate design, which better suits for the detection 
of ADRs of short latency [49]. Further research detailing the nature of the signals detected for 
infections and neoplasms is needed in order to better clarify the relationship between them and 
the use of biologics. 
Another important finding in our results was the association between the use of 
rituximab and the occurrence of blood disorders. An assessment of the long-term safety of 
rituximab in patients with RA has not revealed important serious events [50], but in another 
study that examined the use of rituximab in various pathologies, especially in anti-neoplastic 
therapeutic regimes, researchers have highlighted the occurrence of serious ADRs, including 
blood disorders. [51]. Our results may be due to the variability in indications of use of this drug 
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in comparison to other biologics. In almost 20% of the ADRs, rituximab was indicated for the 
treatment of blood neoplasia, implying that there was a higher frequency of individuals with 
different pathophysiological conditions compared to the usual population that uses the other 
types of biologics. Pathophysiological differences are considered to be one of the determining 
factors in the variability of susceptibility to ADRs [52]. A higher frequency of patients with 
poor prognostic factors, advanced stage of disease, and greater immune system weakness may 
also have influenced these results, considering that rituximab is generally recommended for RA 
for patients who have failed to respond to previous TNFi [23, 54].    
The association between PML and rituximab may be due to the greater immunological 
weaknesses of these patients. A review of the literature has shown that immunocompromised 
patients are more susceptible to PML, and that in cases where this event was observed with the 
use of rituximab, patients were on immunosuppressive medication [53]. The association 
between this event and use of infliximab was highlighted as an important safety concern, 
especially in autoimmune diseases. Although the number of reports associated with infliximab 
was low, careful and intensive monitoring of PML cases associated with biologics is needed [8, 
42].   
Several SDRs were identified in only one subgroup of patients, what suggests that the 
use of disproportionality analyses by subgroups can help to identify groups with greater 
susceptibility to specific adverse events in addition to increasing the sensitivity  for the detection 
of SDRs compared with crude or stratified analyses [31].  
The results of our study provide insight into potential safety issues that need to be 
evaluated by further analytical studies, so as to provide an accurate risk assessment of the 
occurrence of ADRs [54, 55]. We were able to identify a few priorities in order to guide 
clinicians’ investigations.  
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Amongst the drugs, infliximab stood out, as it was most frequently related to the SOCs 
‘infections and infestations’ and ‘malignant and unspecified benign neoplasms’. A literature 
review of randomized controlled trials, meta-analyses, national registry articles, and case 
reports have shown a small, yet significantly increased risk of serious infection in RA patients 
treated with infliximab, etanercept, and adalimumab [56]. Moreover, a few published studies 
have suggested an increased risk of malignancy in RA patients receiving TNFi. However, the 
published literature points out that this result is still inconclusive, and more studies are needed 
to elucidate the association between these therapies and cancer risk [57-59]. 
Rituximab stood out within the SOC ‘blood and lymphatic system disorders’. These 
adverse events were reported in a clinical review on the use of rituximab, showing that almost 
50% of patients with non-Hodgkin lymphoma in use of this biologic presented grade 3 and 4 
cytopenias [51]. Nevertheless, events related to blood and lymphatic system disorders should 
be further investigated in RA patients on treatment with rituximab [60].  
Regarding separate events, attention should be drawn to infliximab, which was related 
to autoimmune hepatitis and angioedema in the present study. The published literature 
encompasses case reports of autoimmune hepatitis triggered by TNFi therapies [61, 62], as well 
as angioedema related to the use of infliximab [63].  
Moreover, several biologics were found to be associated with intestinal perforation and 
pulmonary fibrosis in the present study, which also have been demonstrated in the available 
literature. Tocilizumab, for instance, was related to the occurrence of acute pancreatitis in a 
study addressing a case report and reviewing the data from the FDA Adverse Event Reporting 
System [64]. This drug was also related to increased risk of lower intestinal perforation when 
compared to other biologics [65].  
Other adverse events, such as pulmonary toxicity, have also been associated to the use 
of biologics, notably TNFi, in clinical studies [66]. Lastly, special focus should be given to the 
16 
 
event progressive multifocal leukoencephalopathy, which was the most reported DME 
associated with rituximab in the present study. The events cited above should be prioritized in 
future investigations. 
Although ROR has a good correlation with Relative Risk, it cannot be interpreted as 
such. It is important to identify the drug-reaction pairs with significant ROR, and not the value 
of it as the value is related to the disproportionality between the notifications and not with the 
risk of causing the reaction. The ROR should be interpreted with caution; it can be important 
in the prioritization of signs that should deserve more attention in pharmacovigilance, but it 
cannot be used for guide clinical decisions [55].  
 The use of an international open-source database such as FAERS, which provides a 
large volume of data, allows higher powered statistical analyses and a better ability to detect 
relevant clinical associations between drugs and events [37, 67]. In this context, the 
participation of consumers and health professionals in the process of reporting ADRs is 
essential in order to minimize bias and enable early detection of major adverse events. We 
observed that most of the ADRs related to biologics were reported by consumers. Studies have 
reinforced the importance of this reporting category in pharmacovigilance, with no evidence of 
poor quality and no increase in the reporting of irrelevant events [68, 69]. On the other hand, 
we observed a low frequency of ADRs reported by pharmacists; professionals could lead to a 
substantial improvement in the spontaneous reporting system [70]. A recent analysis showed 
that the low participation of these professionals may be related to the limited access that they 
have to the systems of health care, as well as critical gaps that still exist in the knowledge of 
ADR communication; this reinforces the need for continuous development programs in this 
area [71]. It may be also due to the fact that most biologics are prescribed and monitored in 
hospital settings, without the presence of the pharmacist. 
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Our study has several limitations. Possible biases, such as underreporting, the Weber 
effect, and the effect of notoriety, can overestimate the number of SDRs or delay the detection 
of important ADRs [72, 73]. Underreporting and the Weber effect may have had little influence 
on our results. The variation in underreporting rates is considered small, mainly between drugs 
of the same class or with similar indications [74], and the use of disproportionality methods 
diminishes this bias as it is likely to also occur for the other drugs used as a group comparator 
[68]. The Weber effect is more relevant in the first two years of commercialization [75], and all 
the biologics analyzed in this research have been approved for more than five years, and are no 
longer considered new drugs. In addition, a study suggests that the pattern described by Weber 
has not been observed in most of the modern adverse event reporting into FAERS  [76]. Another 
limitation of the present study was the lack of case-causality assessment derived from clinical 
evaluation of spontaneous reports when performing signal detection. Additionally, reporting 
biases may have occurred in this study as a result of lawyer advertisements in US media on 
adverse events which may increase reporting, and this may have occurred in other countries.  
 The influence of the effect of notoriety should be considered in our results. This effect 
occurs mainly from safety alert publications in relation to a suspected ADR associated with a 
specific drug. The alert can induce greater notification of this ADR, overestimating the 
disproportionality (the ROR value). This effect can also create a ripple effect, which is an 
increase in the notification of the same ADR for all other drugs within the same 
pharmacological class as the suspected drug [77]. The various safety issues that have not yet 
been well established in relation to biologics contribute to the ongoing publication of security 
alerts in relation to these drugs, and may have overestimated the detected signals.  
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5 Conclusion 
In this study we have highlighted potential safety problems associated to the use of 
biologics , particularly rituximab and infliximab, like the association between rituximab and 
blood disorders and PML, besides the association between infliximab and infections and 
neoplasms and PML., These findings should be validated to guide clinicians, regulators and 
industry to focus on the most relevant signals also in addition to the information already 
included in the summary of product characteristics. 
Our results may directly contribute to future research, identifying clinically relevant 
risks and guiding the rational and safe use of these drugs. The benefit/risk ratio of biologics 
appears to remain favorable, considering the high effectiveness  and the low frequency of fatal 
outcomes and/or DMEs associated with the use of these drugs. Further detailed analysis of the 
data is still needed to better characterize the nature of the identified signals, and to investigate 
other associations. 
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Fig. 1 Relative frequencies of total reports, serious reports, and signals of disproportionate 
reporting (SDR) related with each biologic. 
Table 1. General characteristics of spontaneous reports for biologics approved for the treatment of 
rheumatoid arthritis and other autoimmune diseases in the FAERS 
Characteristics of reports  (N = 411,063) 
Patients’ age (years), mean (SD) 51.1 (14.2) 
Frequency of reports by gender (Female %) 268,360 (65.3) 
Reporter (%) 
Consumers 
Physicians 
Other professionals 
Pharmacists 
Not informed 
 
188,963 (46.0) 
141,386 (34.4) 
61,601 (15.0) 
7,285 (1.8) 
11,828 (2.9) 
Reporting origin (%) 
North America 
US 
Europe 
Other continents 
Missing data 
 
235,230 (57.2) 
215,331 (52.4) 
44,823 (10.9) 
22,972 (5.6)  
108,038 (26.3)  
 Report to each biologics (%)* 
TNFi 
Infliximab 
Etanercept 
Adalimumab 
Certolizumab pegol 
Golimumab 
non-TNFi 
Rituximab 
Anakinra 
Abatacept 
Tocilizumab 
 
380,900 (92.7)  
41,920 (10.2) 
172,225 (41.9)  
148,586 (36.1)  
11,419 (2.8)  
6,750 (1.6)  
36,362 (8.8) 
19,788 (4.8) 
655 (0.2) 
9,200 (2.2) 
6,719 (1.6) 
Serious reports (%)* 
IMEs 
Hospitalization or prolongation 
Death 
Risk to life 
Disability 
Need for intervention to prevent permanent damage 
Congenital anomalies 
177,031(43.1) 
108,982 (26.5) 
83,093 (20.2) 
13,192 (3.2) 
7,428 (1.8) 
4,208 (1.0) 
1,560 (0.4) 
75 (0.02) 
Serious reports to each biologics(%)* 
TNFi 
Infliximab 
Etanercept 
Adalimumab 
Certolizumab pegol 
Golimumab 
non-TNFi 
Rituximab 
Anakinra 
Abatacept 
           Tocilizumab 
 
150,710 (85.1)  
39,832 (22.5) 
53,027 (30.0) 
45,284 (25.6)  
7,374 (4.2) 
5,193 (2.9)  
 
31,435 (17.8) 
19,425 (11.0) 
547 (0.3) 
5,016 (2.8) 
6,466 (3.7) 
25 
 
Indication of the use of biologics (%)* 
Rheumatoid arthritis  
Psoriatic disease 
Crohn's disease 
Ankylosing spondylitis 
Colitis ulcerative 
Other indication** 
Unknown indication  
 
173,201 (42.1) 
85,331 (20.8) 
58,082 (14.1) 
20,332 (4.9) 
13,579 (3.3) 
23,841 (5.8) 
39,167 (9.5) 
TNFi = tumor necrosis factor inhibitors,  IMEs = important medical events, FAERS: Adverse Event 
Reporting System, 
 *= a report may contain more than one suspected drug, serious outcome and/or indication of the use,  
**= individual frequency less than 1% 
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Table 2  Distribution of signals of disproportionate reporting (SDR) classified according to the SOC level for the total and stratified by biologic drug (%)
 
 
System Organ Class All biologics 
N = 2.602 
Infliximab 
N = 646 
Etanercept 
N = 329 
 
Adalimumab 
N = 421 
Certolizumab pegol 
N = 172 
Golimumab 
N = 119 
Rituximab 
N = 529 
Anakinra 
N = 51 
Abatacept 
N = 136 
Tocilizumab 
N = 199 
Infections and infestations 32.2  25.3 12.4 16.2 7.5 6.4 17.9 1.8 5.4 7.0 
Neoplasms benign. malignant 
and unspecified 
20.4 28.8 16.5 14.1 5.5 4.1 20.7 1.3 3.8 5.3 
Gastrointestinal disorders 8.2 25.8 3.8 25.4 11.7 3.8 14.1 0.5 3.3 11.7 
Surgical and medical 
procedures 
8.0 28.2 27.8 20.1 6.2 4.3 4.8 1.0 5.3 2.4 
Nervous system disorders 4.5 20.3 6.8 15.3 4.2 4.2 32.2 2.5 7.6 6.8 
Respiratory. thoracic and 
mediastinal disorders 
3.2 22.6 3.6 2.4 7.1 2.4 34.5 4.8 8.3 14.3 
Musculoskeletal and 
connective tissue disorders 
3.2 18.3 20.7 17.1 7.3 7.3 9.8 1.2 7.3 11.0 
Injury. poisoning and 
procedural complications 
2.8 19.4 12.5 34.7 5.6 1.4 12.5 0.0 6.9 6.9 
Eye disorders 2.1 27.3 14.5 16.4 3.6 3.6 18.2 0.0 5.5 10.9 
Blood and lymphatic system 
disorders 
2.0 11.8 5.9 5.9 2.0 2.0 56.9 5.9 0.0 9.8 
Cardiac disorders 1.9 22.0 0.0 2.0 8.0 2.0 30.0 8.0 18.0 10.0 
Immune system disorders 1.8 22.9 10.4 6.3 4.2 0.0 41.7 2.1 4.2 8.3 
Hepatobiliary disorders 1.8 19.1 0.0 12.8 2.1 4.3 36.2 6.4 2.1 17.0 
Renal and urinary disorders 1.6 21.4 9.5 11.9 4.8 7.1 33.3 2.4 2.4 7.1 
Vascular disorders 1.5 15.8 2.6 15.8 2.6 2.6 28.9 5.3 7.9 18.4 
Skin and subcutaneous tissue 
disorders 
1.4 29.7 10.8 13.5 10.8 2.7 16.2 2.7 2.7 10.8 
Other* 3.3 2.6 2.7 4.0 2.3 0.8 4.3 5.9 4.4 3.0 
a: Percentages were calculated based on the total of SDRs with important medical events (N) associated with each biologic drug. 
*: Individual frequency of SDRs less than 1% 
SOC =  System Organ Class 
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Table S1 Keywords used for identified suspect ADRs reported for bDMARDs* in the FAERS 
DRUG BRAND NAME CODES 
A
n
ti
-T
N
F
 b
D
M
A
R
D
s Infliximab  
Remicade, Inflectra, Remsima, Avakine, 
Flammegis, Revellex 
- 
Etanercept Enbrel, Enbrol, Etanar, Yisaipu TNFR Fc 
Adalimumab Humira, Trudexa  D2E7 
Certolizumab pegol Cimzia, Cimizia CDP 870 
Golimumab Simponi  
N
o
n
 a
n
ti
-T
N
F
 b
D
M
A
R
D
s Rituximab 
Rituxan, Mabthera, Ikgdar, Reditux, 
Ristova 
IDEC-C2B8, BI 695500, PF-05280586, IDEC-102, RTXM83 
anti-CD20, GP2013 
Anakinra Kineret, Antril rIL-1ra, rIL1RN 
Abatacept Orencia, Ohrencia, Orenica BMS 188667, LEA 29Y  
Tocilizumab 
Actemra, RoActemra, Aktempa, 
Actembra, Acterma, Atlizumab 
- 
ADR adverse drug reaction, bDMARDs biological disease-modifying antirheumatic drugs, FAERS FDA Adverse Event Reporting System; * bDMARDs approved in the treatment of 
rheumatoid arthritis until june 2016. 
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Table S1 Distribution of ADRs reported for bDMARDs in FAERs 
 
Total 
bDMARDs 
1,339,374 (%) 
Anti-TNF bDMARDs  Non anti-TNF bDMARDs 
Infliximab 
133,443 (10.0) 
Etanercept 
543,916 (40.6) 
Adalimumab 
476,913 (35.6) 
Certolizumab 
pegol 
33,689 (2.5) 
Golimumab 
18,207 (1.4) 
Rituximab 
76,645 (5.7) 
Anakinra 
2,582 (0.2) 
Abatacept 
23,640 (1.8) 
Tocilizumab 
30,339 (2.3) 
Age categories (years)           
18-35 221,237 (16.5) 33,327 (25.0) 60,578 (11.1) 104,405 (21.9) 8,588 (25.5) 2,581 (14.2) 6,861 (9.0) 495 (19.2) 1,405 (5.9) 2,997 (9.9) 
36-64 854,083 (63.8) 76,879 (57.6) 377,541 (69.4) 292,332 (61.3) 19,858 (58.9) 10,910 (59.9) 42,882 (55.9) 1,507 (58.4) 14,872 (62.9) 17,302 (57.0) 
65-74 264,054 (17.7) 23,237 17.4) 105,797 (19.5) 80,176 (16.8) 5,243 (15.6) 4,716 (25.9) 26,902 (35.1) 580 (22.5) 7,363 (31.1) 10,040 (33.1) 
Sex           
Females 912,522 (68.1) 80,751 (60.5) 395,510 (72.7) 315,190 (66.1) 24,222 (71.9) 12,471 (68.5) 41,092 (53.6) 1,674 (64.8) 19,083 (80.7) 22,529 (74.3) 
Males  418,477 (31.2) 51,523 (38.6) 145,953 (26.8) 158,803 (33.3) 9,236 (27.4) 5,599 (30.8) 34,289 (44.7) 892 (34.5) 4,438 (18.8) 7,744 (25.5) 
Missing value 8,375 (0.6) 1,169 (0.9) 2,453 (0.5) 2,920 (0.6) 231 (0.7) 137 (0.8) 1,264 (1.6) 16 (0.6) 119 (0.5) 66 (0.2) 
           
Serious ADRs  704,372 (52.6) 127,900 (95.8) 215,358 (39.6) 199,951 (41.9) 23,826 (70.7) 14,058 (77.2) 75,584 (98.6) 2,368 (91.7) 15,623 (66.1) 29,704 (97.9) 
IMEs 472,848 (35.3) 80,341 (60.2) 166,696 (30.6) 127,394 (26.7) 13,935 (41.4) 9,291 (51.0) 41,037 (53.5) 768 (29.7) 11,619 (49.1) 21,767 (71.7) 
Hospitalization 366,424 (27.4) 60,240 (45.1) 93,172 (17.1) 125,974 (26.4) 13,367 (39.7) 6,080 (33.4) 43,564 (56.8) 1,828 (70.8) 7,216 (30.5) 14,983 (49.4) 
Intervention 6,544 (0.5) 2,526 (1.9) 698 (0.1) 2,301 (0.5) 13 (0.0) 13 (0.1) 854 (1.1) 82 (3.2) 37 (0.2) 20 (0.1) 
Disability/ incapacity 21,844 (1.6) 3,952 (3.0) 4,456 (0.1) 7,455 (1.6) 797 (2.4) 349 (1.9) 2,799 (3.7) 127 (4.9) 532 (2.3) 1,377 (4.5) 
Life-threatening 33,192 (2.5) 8,339 (6.2) 4,718 (0.8) 7,732 (1.6) 880 (2.6) 480 (2.6) 7,374 (9.6) 421 (16.3) 849 (3.6) 2,399 (7.9) 
death 54,324 (4.1) 10,280 (7.7) 8,992 (0.9) 13,573 (2.8) 1,350 (4.0) 516 (2.8) 15,139 (19.8) 444 (17.2) 1,569 (6.6) 2,461 (8.1) 
congenital anomalies 392 (0.0) 62 (0.0) 100 (0.0) 174 (0.0) 16 (0.0) 0 (0.0) 27 (0.0) 0 (0.0) 0 (0.0) 13 (0.0) 
indication for use            
Rheumatoid arthritis 587,004 (43,8) 33,278 (24.9) 316,828 (58.2) 153,269 (32.1) 12,289 (36.5) 8,256 (45.3) 19,396 (25.3) 1,451 (56.2) 16,583 (70.1) 25,654 (84.6) 
Crohn's disease 191,266 (14.3) 37,769 (28.3) 76 (0.0) 137,738 (28.9) 15,352 (45.5) 292 (1.6) 0 (0.0) 0 (0.0) 39 (0.2) 0 (0.0) 
Psoriatic disease 260,440 (19.4) 9,773 (7.3) 144,365 (26.5) 102,988 (21.6) 949 (2.8) 1,988 (10.9) 35 (0.0) 39 (1.5) 247 (1.0) 56 (0.2) 
Ankylosing spondylitis 68,367 (5.1) 6,806 (5.1) 34,931 (6.4) 24,098 (5.1) 572 (1.7) 1,866 (10.2) 31 (0.0) 4 (0.2) 40 (0.2) 19 (0.1) 
Colitis ulcerative 40,846 (3.0) 11,253 (8.4) 30 (0.0) 28,005 (5.9) 318 (0.9) 1,186 (6.5) 1 (0.0) 0 (0.0) 53 (0.9) 0 (0.0) 
other indication* 83,532 (6.2) 8,666 (6.5) 10,393 (1.9) 11,821 (2.5) 661 (2.0) 749 (4.1) 47,273 (61.7) 821 (31.8) 697 (2.9) 2,451 (8.1) 
unknown indication 110,861 (8.3) 26,899 (20.2) 37,798 (6.9) 19,610 (4.1) 3,936 (11.7) 3,888 (21.4) 10,206 (13.3) 352 (13.6) 5,995 (25.4) 2,177 (7.2) 
ADRs adverse drug reaction, DMARDs biological disease-modifying antirheumatic drugs,  FAERS FDA Adverse Event Reporting System, anti-TNF anti-tumor necrosis factor alpha, *: Individual frequency of 
safety signals less than 1% 
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conclusion 
Designed Medical Event (DME) Rituximab ROR (95%CI)* 
Anaphylactic reaction 1.97 (1.06-3.66)a; 1.94 (1.41-2.68)d; 1.99 (1.39-2.85)e; 2.02 (1.29-3.19)h 
Anaphylactoid reaction 3.07 (1.53-6.17)d 
Neutropenic infection 16.70 (9.04-30.87)e; 6.61 (2.08-21.00)g; 3.99 (1.26-12.61)h 
Neutropenic sepsis 6.55 (2.09-20.50)b; 2.17 (1.20-3.93)d; 2.22 (1.26-3.92)e; 6.88 (4.71-10.05)g; 4.36 (2.94-6.44)h 
Progressive multifocal 
leukoencephalopathy 
9.89 (4.40-22.25)a; 14.45 (7.91-26.39)b; 22.91 (19.28-27.21)d; 21.02 (17.36-25.45)e; 57.51 (46.72-70.80)g;  
33.49 (27.03-41.50)h 
Renal failure 3.37 (2.25-5.04)a; 1.48 (1.16-1.88)d 
Pulmonary fibrosis 3.86 (2.53-5.88)d; 3.97 (2.63-6.00)e; 4.11 (2.76-6.12)g; 2.64 (1.80-3.86)h 
ROR reporting odds ratio, DME designed medical event, bDMARDs  biological disease-modifying antirheumatic drugs, *values statistically significant 
ROR for bDMARDs in each subgroup,  CI confidence interval 
Subgroups: a = female (18-35 years); b= male (18-35 years); c = uninformed sex (18-35 years); d = female (36-64 years); e = male (36-64 years); f = sex not 
informed (36-64 years); g = female (65-74 years); h = male (65-74 years); i = uninformed sex (65-74 years); CI: confidence interval 
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Table S1 Designated medical events associated wich Rituximab by calculate ROR                                                                                                                             continue 
Designed Medical Event (DME) Rituximab ROR (95%CI)* 
Agranulocytosis 7.57 (4.68-12.24)a; 6.17 (3.39-11.20)b; 5.29 (4.01-6.98)d; 5.67 (4.56-7.06)e; 5.57 (1.75-17.75)f; 4.22 (2.88-6.19)g; 2.32 (1.53-
3.51)h 
Aplasia pure red cell 2.73 (1.02-7.31)d; 2.68 (1.39-5.17)e 
Aplastic anaemia 3.97 (2.05-7.69)e 
Autoimmune haemolytic anaemia 7.85 (4.42-13.94)d; 14.22 (9.63-21.01)e; 8.15 (4.17-15.94)g; 10.35 (6.63-16.17)h 
Bone marrow failure 7.29 (4.34-12.17)b; 4.91 (3.79-6.35)d; 5.76 (4.75-7.00)e; 4.02 (2.91-5.55)g; 2.67 (1.92-3.69)h 
Febrile neutropenia 10.48 (7.94-13.82)a; 5.84 (3.93-8.68)b; 16.74 (6.48-43.24)c; 5.48 (4.73-6.34)d; 9.49 (8.55-10.53)e; 4.70 (2.56-8.62)f;  
7.21 (6.21-8.36)g; 5.75 (5.05-6.55)h; 2.66 (1.35-5.24)i 
Granulocytopenia 2.29 (1.32-3.95)e 
Haemolysis 2.63 (1.55-4.46)e; 6.72 (3.93-11.48)g 
Haemolytic anaemia 2.47 (1.53-3.99)e; 2.50 (1.34-4.67)g; 2.57 (1.48-4.45)h 
Immune thrombocytopenic purpura 9.33 (4.41-19.75)a; 2.81 (1.46-5.42)d; 4.60 (2.88-7.33)e; 5.14 (2.74-9.65)g; 2.58 (1.28-5.21)h 
Pancytopenia 3.79 (2.31-6.20)a; 4.10 (2.42-6.95)b; 3.93 (3.24-4.77)d; 3.83 (3.26-4.50)e; 4.19 (2.06-8.51)f; 2.70 (2.14-3.42)g; 2.75 (2.24-3.37)h 
Thrombotic thrombocytopenic purpura 7.13 (2.65-19.17)a; 2.81 (1.33-5.91)d 
Deafness 2.31 (1.39-3.84)d 
Sudden hearing loss 5.98 (2.22-16.11)d 
Blindness 1.95 (1.28-2.96)e 
Intestinal perforation 2.02 (1.01-4.06)d; 3.24 (1.83-5.73)g 
Neutropenic colitis 4.02 (1.29-12;56)d; 8.03 (3.77-17.08)e; 11.02 (4.44-27.32)g; 5.34 (1.68-16.98)h 
Acute hepatic failure 4.71 (3.28-6.77)e 
Hepatic failure 2.58 (2.03-3.27)e; 2.08 (1.34-3.24)g; 1.93 (1.35-2.75)h 
Hepatitis fulminant 6.44 (4.17-9.94)e; 7.89 (3.69-16.86)g; 3.62 (1.93-6.79)h 
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Table S2 Designated medical events associated wich other non anti-TNF bDMARDs by calculate ROR                                                                                                           
Designed Medical Event (DME) Anakinra ROR (95%CI)* Abatacept ROR (95%CI)* Tocilizumab ROR (95%CI)* 
Haemolysis - - 19.77 (6.31-61.93)b 
Sudden hearing loss - - 9.65 (3.05-30.54)g 
Intestinal perforation - 3.38 (1.60-7.10)d 5.15 (2.84-9.33)d; 
4.12 (1.71-9.94)e; 
 6.66 (3.92-11.32)g 
Pancreatitis 9.19 (2.95-28.63)
g - - 
Pancreatitis acute - - 8.03 (2.99-21.52)
b 
Acute hepatic failure 35.10 (11.15-110.52)
b - - 
Drug-induced liver injury - - 2.07 (1.03-4.14)d 
Hepatic necrosis 26.40 (8.45-82.50)a - - 
Anaphylactic reaction - 3.72 (1.54-8.95)a; 
1.85 (1.18-2.90)d; 
2.72 (1.26-2.32)e; 
2.04 (1.02-4.10)g  
5.05 (1.62-15.74)b; 
2.69 (1.07-2.69)d; 
3.16 (1.79-5.57)e 
Anaphylactic shock 6.02 (1.94-18.70)d - - 
Renal failure 5.46 (3.08-9.67)e - - 
Pulmonary fibrosis - 7.05 (3.16-15.73)e; 
5.29 (3.12-8.98)g; 
3.37 (1.26-9.00)h 
2.71 (1.02-7.24)e; 
3.41(1.93-6.04)g; 
3.30 (1.48-7.36)h 
ROR reporting odds ratio, DME designed medical event, bDMARDs biological disease-modifying antirheumatic drugs, *values statistically significant ROR for bDMARDs in 
each subgroup, CI confidence interval 
Subgroups: a = female (18-35 years); b= male (18-35 years); c = uninformed sex (18-35 years); d = female (36-64 years); e = male (36-64 years); f = sex not informed (36-64 
years); g = female (65-74 years); h = male (65-74 years); i = uninformed sex (65-74 years); CI: confidence interval 
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Table S3 Designated medical events associated wich anti-TNF bDMARDs by calculate of ROR                                                                                                          
Evento Médico Designado (DME) Infliximab Etanercept Adalimumab Certolizumab pegol Golimumab 
Aplastic anaemia - - - 5.69 (1.81-17.83)a - 
Deafness - 1.73 (1.02-2.94)h - - - 
Sudden hearing loss 5.10 (1.59-16.32)a - 2.22 (1.24-3.98)d - - 
Intestinal perforation 6.62 (4.04-10.84)a; 6.50 (3.95-10.69)b; 
4.04 (2.82-5.77)d;  
3.55 (2.42-5.20)e; 2.85 (1.53-5.32)h 
- 7.25 (5.36-9.81)a; 
7.16 (5.14-9.98)b; 1.55 
(1.17-2.06)d; 
1.71 (1.26-2.32)e  
8.91 (4.20-18.90)a; 
7.40 (2.75-19.93)b; 
6.73 (3.49-12.98)e 
3.24 (1.21-8.66)d 
Pancreatitis 1.78 (1.30-2.45)a; 2.11 (1.40-3.19)g - - 2.16 (1.27-3.65)a; 
4.06 (1.82-9.07)h 
- 
Autoimmune hepatitis 3.58 (2.06—6.23)a;  
6.66 (3.22-13.76)b; 
3.18 (2.17-4.65)d; 3.00 (1.60-5.62)e 
- - - - 
Anaphylactic reaction 2.66 (2.05-3.45)a; 2.70 (1.89-3.84)b; 
2.00 (1.60-2.51)d 
- - - - 
Anaphylactic shock 2.10 (1.39-3.17)a; 2.03 (1.54-2.67)d; 
1.50 (1.03-2.20)e 
- - - - 
Anaphylactoid reaction 2.54 (1.26-5.14)a; 3.92 (1.83-8.38)b; 
3.94 (2.52-6.14)d 
- - - - 
Neutropenic sepsis - - - - 7.71 (2.88-20.63)h 
Progressive multifocal 
leukoencephalopathy 
4.73 (2.67-8.39)h - - - - 
Pulmonary fibrosis 2.76 (1.93-3.93)c; 2.14 (1.38-3.33)e; 
12.41 (3.78-40.70)f;  
3.74 (2.52-5.57)g; 2.60 (1.61-4.20)h 
1.28 (1.03-1.59)d; 
1.76 (1.35-2.30)e; 
2.09 (1.65-2.65)g; 
1.73 (1.23-2.43)h 
1.63 (1.20-2.22)g;  
2.02 (1.45-2.81)h 
3.68 (1.65-8.21)e; 
3.48 (1.56-7.77)g; 
8.72 (4.67-16.28)h 
- 
Angioedema 1.52 (1.05-2.22)a; 
1.52 (1.16-1.98)d; 1.61 (1.17-2.21)e 
- - - - 
ROR reporting odds ratio, DME designed medical event, bDMARDs  biological disease-modifying antirheumatic drugs, *values statistically significant ROR for bDMARDs 
in each subgroup,  CI confidence interval 
Subgroups: a = female (18-35 years); b= male (18-35 years); c = uninformed sex (18-35 years); d = female (36-64 years); e = male (36-64 years); f = sex not informed (36-64 
years); g = female (65-74 years); h = male (65-74 years); i = uninformed sex (65-74 years); CI: confidence interval
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